View web version.

Best Practices in the Evolving and Complex Lung Cancer Testing Journey

Objectives:

  • Learn about the evolving biomarker NSCLC landscape and how comprehensive genomic profiling (CGP) is the new standard of care in lung cancer testing.

  • An update to What the Guidelines Say About Biomarker Testing

  • Best practices to maximize tissue preservation and optimize tumor profiling during diagnosis and prognosis, including liquid biopsy.

  • How testing dynamics is impacting the community vs. the academic setting, and barriers to care.

  • Case study review: Choosing cancer Tests to Fit Circumstances to make therapeutic decisions
Watch

Hatim Husain, MD

Associate Professor of Medicine
UC San Diego Health

 

Shari Brown, MD PhD

Director of Molecular Pathology at NeoGenomics

 

MJH Life Sciences
This email was sent by: %%Member_Busname%%
%%Member_Addr%%, %%Member_City%%, %%Member_State%%, %%Member_PostalCode%% %%Member_Country%%

Privacy Policy

Update Profile      Manage Subscriptions      Unsubscribe

Clicking here does not unsubscribe you from Bristol Myers Squibb emails.